ONCOLife Issues
Featured Articles
Trending Articles
Trodelvy Emerges as Potential New Standard for First-Line Metastatic TN Breast Cancer
ONCOLife | 24 October 2025
Datroway Extends Survival by 5 Months in Metastatic Triple-Negative Breast Cancer
ONCOLife | 21 October 2025
Lenvatinib Plus Pembrolizumab Delivers Durable 5-Year Survival in Endometrial Carcinoma
ONCOLife | 20 October 2025
Disarming Prostate Cancer: Dual Enzyme Blockade Weakens Tumors and Boosts Drug Response
ONCOLife | 14 October 2025
Reprogramming Cancer Cell Death: A New Immune-Based Strategy for Blood Cancers
ONCOLife | 12 October 2025
In Vivo CAR T on the Horizon: BMS Acquires Orbital to Expand Cell Therapy Reach
Pharma | 10 October 2025
AstraZeneca makes deal with Trump Admin to Cut Drug Prices 80% and Invest $50B in US
Pharma | 11 October 2025
FDA Approves Libtayo as First Adjuvant Immunotherapy for High-Risk CS Cell Carcinoma
FDA & EMA | 9 October 2025
Datroway Improves Survival in First-Line Treatment of Metastatic Triple- Breast Cancer
ONCOLife | 6 October 2025
FDA Approves Tecentriq–Zepzelca Combo as FL Maintenance Therapy for ES-SC Lung Cancer
FDA & EMA | 3 October 2025
Dr. Eleni Lagkadinou Discusses How AbbVie Is Advancing Targeted Innovation for HT Cancers
ONCOLife | 1 October 2025
FDA Approves Imlunestrant for ESR1-Mutated Metastatic Breast Cancer
FDA & EMA | 27 September 2025
NEJM Study Confirms Low-Dose Aspirin Halves Recurrence in Colorectal Cancer
Clinical Trials
20 September 2025
EMA’s CHMP Backs Subcutaneous Pembrolizumab in Head and Neck Cancer
FDA & EMA
19 September 2025
FDA Grants Breakthrough Status to Raludotatug Deruxtecan for Refractory Ovarian Cancer
ONCOLife
17 September 2025
GSK to invest $30 billion in R&D and Manufacturing in the US over next 5 years
Pharma
18 September 2025
The Role of Third-Generation TKIs in Overcoming Chronic Myeloid Leukemia Resistance
ONCOLife
17 September 2025
SUNMO Trial: A New Chapter for Transplant-Ineligible Large B-Cell Lymphoma
ONCOLife
15 September 2025
CVC and V Foundation Fuel $500K Grant for Next Phase of Breast Cancer Vaccine Research
ONCOLife
10 September 2025
The V Foundation for Cancer Research and CVC Partner to Accelerate Breast Cancer Vaccines
ONCOLife
29 August 2025
FDA Grants Breakthrough Status to Izalontamab Brengitecan for EGF+ Lung Cancer
FDA & EMA
20 August 2025